These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35496970)

  • 21. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.
    Correa DD; Braun E; Kryza-Lacombe M; Ho KW; Reiner AS; Panageas KS; Yahalom J; Sauter CS; Abrey LE; DeAngelis LM; Omuro A
    J Neurooncol; 2019 Sep; 144(3):553-562. PubMed ID: 31377920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
    J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).
    Rubenstein JL; Hsi ED; Johnson JL; Jung SH; Nakashima MO; Grant B; Cheson BD; Kaplan LD
    J Clin Oncol; 2013 Sep; 31(25):3061-8. PubMed ID: 23569323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.
    Zhao D; Qian L; Shen J; Liu X; Mei K; Cen J; Wang Y; Li C; Ma Y
    J Cell Mol Med; 2014 Jun; 18(6):1081-6. PubMed ID: 24628986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.
    Ekenel M; Iwamoto FM; Ben-Porat LS; Panageas KS; Yahalom J; DeAngelis LM; Abrey LE
    Cancer; 2008 Sep; 113(5):1025-31. PubMed ID: 18618509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma.
    Lee TH; Lee JH; Chang JH; Ye SJ; Kim TM; Park CK; Kim IH; Kim BH; Wee CW
    Radiat Oncol J; 2020 Mar; 38(1):35-43. PubMed ID: 32229807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of radiation therapy in primary central nervous system lymphoma : KROG 14-20 Collaborative Study of Brain and Lymphoma Committee.
    Koh HK; Kim IH; Kim TM; Lim DH; Oh D; Cho JH; Kim WC; Kim JH; Chung WK; Jeong BK; Kang KM; Hong S; Suh CO; Kim IA
    J Neurooncol; 2017 Dec; 135(3):629-638. PubMed ID: 28939931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
    Nagane M
    Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
    Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
    Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?
    Omuro A; Taillandier L; Chinot O; Sierra Del Rio M; Carnin C; Barrie M; Soussain C; Tanguy ML; Choquet S; Leblond V; Hoang-Xuan K;
    J Neurooncol; 2011 Aug; 104(1):323-30. PubMed ID: 21170569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
    Omuro A; Correa DD; DeAngelis LM; Moskowitz CH; Matasar MJ; Kaley TJ; Gavrilovic IT; Nolan C; Pentsova E; Grommes CC; Panageas KS; Baser RE; Faivre G; Abrey LE; Sauter CS
    Blood; 2015 Feb; 125(9):1403-10. PubMed ID: 25568347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partial-brain radiotherapy for primary central nervous system lymphoma: multi-institutional experience.
    Iwabuchi M; Shibamoto Y; Sugie C; Ayakawa S; Ogino H; Baba F
    J Radiat Res; 2016 Mar; 57(2):164-8. PubMed ID: 26661856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51.
    Laack NN; Ballman KV; Brown PB; O'Neill BP;
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1429-39. PubMed ID: 16863926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study.
    Lesueur P; Damaj G; Hoang-Xuan K; Roland V; Schmitt A; Chinot O; Fabbro M; Agapé P; Moluçon-Chabrot C; Chebrek S; Alentorn A; Feuvret L; Delgadillo D; Stefan D; Choquet S; Nichelli L; Mokhtari K; Mathon B; Dureau S; Soussain C; Houillier C
    Blood Adv; 2022 Aug; 6(16):4807-4815. PubMed ID: 35772168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis.
    Epperla N; Reljic T; Chowdhury SM; Ferreri AJM; Kumar A; Hamadani M
    Hematol Oncol; 2023 Feb; 41(1):88-96. PubMed ID: 36192141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.
    DeAngelis LM; Seiferheld W; Schold SC; Fisher B; Schultz CJ;
    J Clin Oncol; 2002 Dec; 20(24):4643-8. PubMed ID: 12488408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes with reduced-dose whole-brain radiotherapy and a stereotactic radiosurgery boost for primary central nervous system lymphoma.
    Foreman BE; Mullikin TC; Floyd SR; Kelsey CR; Patel MP; Peters KB; Kirkpatrick JP; Reitman ZJ; Vaios EJ
    Neurooncol Adv; 2023; 5(1):vdad097. PubMed ID: 37706200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China.
    Sun X; Wu Y; Xing R; Bai X; Qian J; Zhu H; Cui Q; Chen Y; Liu Q; Lai W; Li J; Wang Y; Sun S; Gao C; Ji N; Liu Y
    Front Oncol; 2022; 12():792274. PubMed ID: 35280789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.